REN and prostate cancer: Regarding prostate cancer, we obtained consistent findings that taking genetically susceptible agents acting on the renin-angiotensin system (OR = 0.93; 95% CI = 0.90–0.96, P < 0.00001) reduced the odds of prostate cancer, while vasodilators used in cardiac diseases (OR = 1.28; 95% CI = 1.17–1.41, P < 0.00001) increased the odds of prostate cancer.